Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teicoplanin in Clostridium difficile infection
NCT04003818Phase 4Terminated
- Sponsor
- Sanofi
- Start
- May 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teicoplanin in Clostridium difficile infection (CDI), sponsored by Sanofi. Primary endpoints: Clinical Cure Rate, Recurrence Rate at 10 weeks and 1 more. Started May 2020; status: terminated.
02
Drugs
teicoplanin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT04003818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003818.